(2026). Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). Rheumatology and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)."
Rheumatology and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)."
Rheumatology and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.